Navigation Links
BD Announces Results For 2011 Third Fiscal Quarter
Date:8/2/2011

FRANKLIN LAKES, N.J., Aug. 2, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.014 billion for the third fiscal quarter ended June 30, 2011, representing an increase of 10.0 percent from the prior-year period.  On a foreign currency-neutral basis, revenues increased 4.8 percent.

“We are pleased with our solid results this quarter, with all three segments contributing to growth,” said Edward J. Ludwig, Chairman and Chief Executive Officer.  “Gross margin expansion reflecting favorable product mix has offset some of the headwinds we have been facing as a result of a challenging macroeconomic environment and increased raw material costs.”

Agreement to Acquire Carmel Pharma, ABOn July 27, 2011, the Company announced that it had signed a definitive agreement to acquire Carmel Pharma, AB, a Swedish company that manufactures the PhaSeal® System. This is the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.  The acquisition is expected to close prior to the end of this fiscal year.

Third Quarter and Nine-Month Fiscal 2011 Operating ResultsReported diluted earnings per share from continuing operations for the third quarter were $1.51, compared with $1.23 in the prior-year period, representing a 22.8 percent increase, or 13.8 percent on a currency-neutral basis.

For the nine-month period ending June 30, 2011, reported diluted earnings per share from continuing operations were $4.23, compared with $3.66 in the prior-year period. The prior-year period included a non-cash charge of $8.9 million, or $0.04 per share, related to healthcare reform impacting Medicare Part D reimbursements. Excluding that item, earnings per share from continuing operations incr
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
2. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
3. SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion
4. Hologic Announces Third Quarter Fiscal 2011 Operating Results
5. Medela Announces 2011 Breastfeeding Hall of Excellence Inductees to Nationally Recognize Exceptional Breastfeeding Advocates
6. Misonix Announces New Distribution Agreement for Chile
7. Kensey Nash Corporation Announces Its Fourth Quarter and Fiscal Year End 2011 Earnings Release Date and Teleconference
8. Omnicell Announces Second Quarter 2011 Results
9. BioMarin Announces Second Quarter 2011 Financial Results
10. McNeil Consumer Healthcare Announces Plans for New Dosing Instructions for TYLENOL® Products
11. VeraLight Announces CE Mark Approval of the SCOUT DS® for Noninvasive Diabetes Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  In Detroit, where three ... mortality rate is two and one half times of the ... 6 of 10 infants that die in Detroit ... sobering statistics that Covenant Community Care, a faith-based, charitable non-profit ... poised to change thanks to a charitable donation by Konica ...
(Date:4/17/2015)... , April 17, 2015  Over the next five years, ... to grow, with ArcView predicting that 14 more states will ... marijuana. The U.S. market for legal cannabis grew 74 percent ... 2013. Analysts project the market could grow more than fourfold ... states soften their stance on marijuana. Cannabiz Mobile ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has announced ... in 2014 - a Perspective of Diabetes Patient Groups ... This independent study, funded by the author, represents ... in diabetes on the corporate reputation of 14 individual ... whole) in 2014. The results from the respondent diabetes ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... Fla. (PRWEB) April 17, 2015 Most ... of dental restoration units are made overseas by foreign ... Additionally, domestic labs remain unregulated in more than 40 ... The National Association of Dental Laboratories has ... to raise awareness among patients about the consequences that ...
(Date:4/17/2015)... NY (PRWEB) April 17, 2015 ... with a multicenter team of U.S. and Venezuelan ... bacteria yet in humans among an isolated tribe ... of Venezuela. Bacterial diversity in the Yanomami, previously ... to be nearly double that of people living ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog ... auto insurance quotes . , The online environment ... their cars. Drivers should always compare multiple car insurance ... market is a competitive one, which means that customers ... , It is now possible to compare online car ...
(Date:4/17/2015)... Nomedexamlifeinsurance.com has released a new blog post ... smokers . , Smoking is linked to numerous diseases ... will charge smokers more money for life insurance plans. ... insurance and can qualify for advantageous offers. , ... than for non-smokers. Comparing quotes is the best method ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:National Association Urges Transparency in Dental Industry 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Life Insurance Quotes for Smokers Available Online 2
... , , , , ... in the European Journal of Clinical Microbiological Infectious Diseases ... agent in topical wound care, particularly where antibiotic resistance is an ... activity of medical-grade Leptospermum honey: antibacterial spectrum, resistance and ...
... , , , ... could tell people,s personalities based on the types of drink they enjoy. ... described as sweet and indulgent, while someone who likes fruity drinks could ... Los Angeles-based BLD & Grace Restaurants says the same could be said ...
... non-small-cell lung cancer study , MONDAY, July 27 (HealthDay News) ... for people with stage 3A non-small-cell lung cancer, a new ... cannot cure the disease because it has spread to the ... Non-small-cell lung cancer accounts for about 80 percent of lung ...
... a grant of over 39,000 from the charity Deafness Research ... deafness in children and adults and the development of therapies ... of other tumours are caused by mutations affecting a protein ... of cell types including Schwann cells in the nervous system. ...
... 2009) -- For the 29,000 patients in the United States ... treatment that has been shown to improve survival. But for ... in their DNA means that this treatment could result in ... to a high risk of bacterial infection and possible ...
... enzyme, endothelin converting enzyme-2 (ECE-2), may cause the decrease ... disease and contribute to progression of the disease. ... Scholar and colleagues at the University of Bristol,s Dementia ... 2009] of the American Journal of Pathology. ...
Cached Medicine News:Health News:Paper Highlights Antimicrobial Effectiveness of Medical-Grade Honey in Topical Wound Care 2Health News:Personality in a Cup 2Health News:Personality in a Cup 3Health News:Radiation Plus Chemo a Good Option in Lung Cancer 2Health News:Grant for brain tumor and deafness research 2Health News:Genetic testing may be valuable in treating colorectal cancer 2Health News:Blood flow in Alzheimer's disease 2
Designated most popular model or size. 4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Double-ended. Semi sharp. Curved 3 mm tips. Angled right and left....
Double-ended. 6 mm x 9 mm and 6 mm x 11 mm tips....
Medicine Products: